Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy.

Taiwo B, Yanik EL, Napravnik S, Ryscavage P, Koletar SL, Moore R, Mathews WC, Crane HM, Mayer K, Zinski A, Kahn JS, Eron JJ; CFAR Network of Integrated Clinical Systems (CNICS) Cohort Study.

AIDS. 2013 Jun 19;27(10):1593-602. doi: 10.1097/QAD.0b013e3283601115.

2.
3.

Incidence, timing, and determinants of bacterial pneumonia among HIV-infected patients: data from the ICONA Foundation Cohort.

Mussini C, Galli L, Lepri AC, De Luca A, Antinori A, Libertone R, Angarano G, Bonfanti P, Castagna A, DʼArminio Monforte A; ICONA Foundation Study Group.

J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):339-45. doi: 10.1097/QAI.0b013e318295ab85.

PMID:
23591636
4.

Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.

Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, d'Arminio Monforte A, Phillips A, Lundgren JD, Kirk O; EuroSIDA study group.

AIDS. 2012 Jan 28;26(3):315-23. doi: 10.1097/QAD.0b013e32834e8805.

PMID:
22112597
5.

Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada.

Samji H, Taha TE, Moore D, Burchell AN, Cescon A, Cooper C, Raboud JM, Klein MB, Loutfy MR, Machouf N, Tsoukas CM, Montaner JS, Hogg RS; Canadian Observational Cohort (CANOC) Collaboration.

HIV Med. 2015 Feb;16(2):76-87. doi: 10.1111/hiv.12173. Epub 2014 Sep 1.

6.

Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old.

Siegfried N, Davies MA, Penazzato M, Muhe LM, Egger M.

Cochrane Database Syst Rev. 2013 Oct 10;(10):CD010309. doi: 10.1002/14651858.CD010309.pub2. Review.

7.

Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.

Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T, Gaolathe T, Ndwapi N, Mawoko N, Widenfelt E, Moyo S, Musonda R, Mine M, Makhema J, Moffat H, Essex M, Degruttola V, Marlink RG.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):37-46. doi: 10.1097/QAI.0b013e31819ff102.

8.

Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy.

Lacombe JM, Boue F, Grabar S, Viget N, Gazaignes S, Lascaux-Cametz AS, Pacanowski J, Partisani M, Launay O, Matheron S, Rosenthal E, Rouveix E, Tattevin P, de Truchis P, Costagliola D, Goedert JJ.

AIDS. 2013 Feb 20;27(4):635-43. doi: 10.1097/QAD.0b013e32835cba6c.

9.

Toxicity-related antiretroviral drug treatment modifications in individuals starting therapy: a cohort analysis of time patterns, sex, and other risk factors.

Perović Mihanović M, Haque NS, Rutherford GW, Zekan Š, Begovac J.

Med Sci Monit. 2013 Jun 21;19:483-92. doi: 10.12659/MSM.889283.

10.

Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma.

Kowalkowski MA, Mims MP, Amiran ES, Lulla P, Chiao EY.

PLoS One. 2013 Oct 2;8(10):e77409. doi: 10.1371/journal.pone.0077409. eCollection 2013.

11.

Reduced renal function is associated with progression to AIDS but not with overall mortality in HIV-infected Kenyan adults not initially requiring combination antiretroviral therapy.

Gupta SK, Ong'or WO, Shen C, Musick B, Goldman M, Wools-Kaloustian K.

J Int AIDS Soc. 2011 Jun 11;14:31. doi: 10.1186/1758-2652-14-31.

12.

Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.

Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte Ad, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD.

Arch Intern Med. 2006 Aug 14-28;166(15):1632-41.

PMID:
16908797
13.

Laboratory and clinical predictors of disease progression following initiation of combination therapy in HIV-infected adults in Thailand.

Duong T, Jourdain G, Ngo-Giang-Huong N, Le Cœur S, Kantipong P, Buranabanjasatean S, Leenasirimakul P, Ariyadej S, Tansuphasawasdikul S, Thongpaen S, Lallemant M; Program for HIV Prevention and Treatment Study Group.

PLoS One. 2012;7(8):e43375. Epub 2012 Aug 15.

14.

Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis.

Puoti M, Cozzi-Lepri A, Paraninfo G, Arici C, Moller NF, Lundgren JD, Ledergerber B, Rickenbach M, Suarez-Lozano I, Garrido M, Dabis F, Winnock M, Milazzo L, Gervais A, Raffi F, Gill J, Rockstroh J, Ourishi N, Mussini C, Castagna A, De Luca A, Monforte Ad; HBV-HIV International Intercohort Study Group.

Antivir Ther. 2006;11(5):567-74. Erratum in: Antivir Ther. 2006;11(6):831. Paraninfo, Giuseppe [added].

PMID:
16964824
15.

Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.

Mocroft A, Staszewski S, Weber R, Gatell J, Rockstroh J, Gasiorowski J, Panos G, Monforte Ad, Rakhmanova A, Phillips AN, Lundgren JD; EuroSIDA study group.

Antivir Ther. 2007;12(3):325-33. Erratum in: Antivir Ther. 2007;12(4):577.

PMID:
17591022
16.

AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A.

JAMA. 1999 Dec 15;282(23):2220-6.

PMID:
10605973
17.

The influence of patient beliefs and treatment satisfaction on the discontinuation of current first-line antiretroviral regimens.

Casado JL, Marín A, Romero V, Bañón S, Moreno A, Perez-Elías MJ, Moreno S, Rodriguez-Sagrado MA.

HIV Med. 2016 Jan;17(1):46-55. doi: 10.1111/hiv.12280. Epub 2015 Jul 6.

PMID:
26149493
18.

Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy?

Kousignian I, Launay O, Mayaud C, Rabaud C, Costagliola D, Abgrall S; FHDH-ANRS CO4.

J Antimicrob Chemother. 2010 Jan;65(1):138-44. doi: 10.1093/jac/dkp402.

PMID:
19903719
19.

Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.

Lapadula G, Cozzi-Lepri A, Marchetti G, Antinori A, Chiodera A, Nicastri E, Parruti G, Galli M, Gori A, Monforte Ad; ICONA Foundation Study.

AIDS. 2013 Mar 13;27(5):769-79. doi: 10.1097/QAD.0b013e32835cb747.

PMID:
23719349
20.

Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan.

Tseng YT, Yang CJ, Chang SY, Lin SW, Tsai MS, Liu WC, Wu PY, Su YC, Luo YZ, Yang SP, Hung CC, Chang SC.

Int J Infect Dis. 2014 Dec;29:12-7. doi: 10.1016/j.ijid.2014.08.012. Epub 2014 Oct 12.

Supplemental Content

Support Center